---
title: The Effect of Sumatriptan and Placebo on CGRP Induced Headache
nct_id: NCT03542357
overall_status: COMPLETED
phase: NA
sponsor: Danish Headache Center
study_type: INTERVENTIONAL
primary_condition: Migraine
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03542357.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03542357"
ct_last_update_post_date: 2019-09-12
last_seen_at: "2026-05-12T07:14:58.113Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of Sumatriptan and Placebo on CGRP Induced Headache

**NCT ID:** [NCT03542357](https://clinicaltrials.gov/study/NCT03542357)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Danish Headache Center
- **Conditions:** Migraine
- **Start Date:** 2018-02-15
- **Completion Date:** 2018-09-01
- **CT.gov Last Update:** 2019-09-12

## Brief Summary

To develop a pragmatic migraine model the investigators will induce headache in healthy volunteers and in patients with migraine without aura with aCalcitonine Gene Related Peptide (CGRP). If the headache responds to sumatriptan, the model can be used to test new drug candidates.

## Detailed Description

There remains a great need for more effective anti-migraine drugs with fewer side effects. Human experimental models are valuable in early phase development of new anti-migraine drugs but useful models have not yet been developed. The investigators' group has shown that Calcitonine Gene Related Peptide (CGRP) induce headache/migraine in both healthy volunteers and in patients with migraine without aura (MO). To validate this model, the headache must respond to specific migraine treatment with sumatriptan.

Hypothesis: CGRP induces a migraine-like headache in both healthy subjects and in MO-patients and induced headache responds to a specific anti migraine drug; sumatriptan.

Aim: Developing a pragmatic and valid model for the testing of new anti-migraine drugs.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion criteria:

Healthy:

Healthy subjects of both sexes Age 18-60 years Weight 45-95 kg. Females were requested to use effective contraception.

Migraine patients:

Migraine patients who meet IHS criteria for migraine with or without aura of both sexes 18-60 years 45-95 kg.

Exclusion Criteria:

Healthy:

Any type of headache (except episodic tension-type headache \< 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily medication (except oral contraceptives).

Migraine patients:

Any other type of headache then migraine without aura (except episodic tension-type headache \< 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily medication (except oral contraceptives) Triptan non-responders
```

## Arms

- **Sumatriptan** (ACTIVE_COMPARATOR) — headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg as a pre-treatment
- **Placebo** (PLACEBO_COMPARATOR) — headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of placebo as a pre-treatment

## Interventions

- **Calcitonin Gene Related Peptide** (DRUG) — CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
- **Sumatriptan 50 mg** (DRUG) — CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
- **Placebo Oral Tablet** (DRUG) — CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

## Primary Outcomes

- **AUC after infusion** _(time frame: 1 year)_ — The investigators will assess the outcome measures 1 year after the beginning of the study

## Locations (1)

- Rigshospitalet Glostrup, Glostrup Municipality, Denmark

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.rigshospitalet glostrup|glostrup municipality||denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03542357.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03542357*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*